Data cannot be shared publicly because the each patients could be imaginable from the clinical dataset including age, sex, visiting date and period of admission. Data are available from the Okinawa Chubu Hospital Ethics Committee (contact via the study protocol (H28-64) <https://chubuweb.hosp.pref.okinawa.jp/contact.html>) for researchers who meet the criteria for access to confidential data.

Introduction {#sec001}
============

As post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) as a complication of ERCP may become fatal, the main concern among endoscopists is gaining access into the bile duct without unintentional cannulation at the pancreatic duct \[[@pone.0235757.ref001]\]. Selective bile duct cannulation (SBDC) is essential for ERCP-related procedures \[[@pone.0235757.ref002]\], and the endoscopist should overcome SBDC as the first step in any ERCP cases. Multiple approaches have been developed to achieve SBDC in difficult cases. Pancreatic wire-guided cannulation is the method of choice during unintentional pancreatic guidewire insertion \[[@pone.0235757.ref003],[@pone.0235757.ref004]\]. Needle-knife precut papillotomy and needle-knife fistulotomy are relatively safe techniques especially when performed by experienced hands \[[@pone.0235757.ref005]--[@pone.0235757.ref007]\]. Theoretically, the safest and least invasive way to predict difficult SBDC cases is to specify the image to delineate "a difficult SBDC case" either on a side-viewing endoscopy or a curved linear array endoscopic ultrasound (CLAEUS), by which countermeasures would be decided prior to the cannulation. With regard to side-viewing scope findings, SBDC is reported difficult when the duodenal papilla is extremely small \[[@pone.0235757.ref008]\], when the duodenal papilla contains a peri-ampullary diverticulum (PAD), or when the duodenal papilla has a large oral protrusion \[[@pone.0235757.ref009],[@pone.0235757.ref010]\]. With regard to EUS findings, we reported in a pilot study reporting that CLAEUS findings at the second portion of the duodenum (D2), such as pressure-induced bile duct collapse at D2 and simultaneous depiction of bile and pancreatic ducts at D2, could predict difficult SBDC \[[@pone.0235757.ref011]\]. Given the fact that our pilot study compared only a limited number of patients, well-designed retrospective or prospective study should be performed to verify the above argument. Thus, this study aimed to find specific CLAEUS findings that would enable prediction of difficult SBDC on ERCP.

Materials and methods {#sec002}
=====================

Ethics {#sec003}
------

The institutional review board of Okinawa Chubu Hospital approved the study protocol (H28-64). Because of the retrospective nature of this study and de-identification of personal data, the board waived the need for informed consent. All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000.

Selection and description of participants {#sec004}
-----------------------------------------

This was a single-center observational study conducted at a tertiary referral center with 550 hospital beds and 14 ICU beds, between July 2014 and June 2017. In this study, we enrolled all patients who underwent CLAEUS prior to initial therapeutic ERCP procedures. The demographic information of the patients and related characteristics were obtained from in-hospital electronic medical records. Data collected for analysis included age, sex, ERCP (emergency or not), final diagnosis, side-viewing endoscopic findings (size of the duodenal papilla, characteristics of the duodenal papilla, and PAD), CLAEUS findings \[pressure-induced bile duct collapse at D2, simultaneous depiction of bile and pancreatic ducts at D2 ("simultaneous depiction"), and common bile duct (CBD) diameter\], and cases of successful and difficult SBDC according to the following definition.

Patients were divided into two groups: the straightforward group (S group), which comprised patients whose successful SBDC was completed within 20 min, and the refractory group (R group), which comprised patients whose successful SBDC was completed after more than 20 min, patients for whom the precut method was necessary, patients in whom the procedure was performed under CLAEUS guidance (including the rendezvous technique or choledochoduodenostomy), and patients who required a percutaneous transhepatic approach.

Patients were excluded from the study if they met any of the following criteria: 1) patients who had a tumor of the duodenal papilla or tumor invasion in the papilla (a tumor at the pancreatic head), 2) patients with surgically altered gastrointestinal or pancreatobiliary anatomy, 3) patients whose endosonographic image of a D2 did not include the duodenal papilla, bile duct, or pancreatic duct (no D2 and/or duodenal papilla images available), 4) patients whose CLAEUS were performed at outside facilities, 5) patients whose ERCP was suspended due to sudden change in physical condition including cardiopulmonary arrest, 6) patients who were scheduled for and/or actually underwent pancreatic duct cannulation without bile duct cannulation during ERCP, 7) patients who underwent CLAEUS without D2 evaluation (e.g., only for EUS fine-needle aspiration either from the esophagus or stomach, cystogastrostomy from the stomach or celiac plexus neurolysis from the stomach), 8) patients with impacted biliary stone at the duodenal papilla, and 9) patients with fluid accumulation, cysts, calcification adjacent to the ampulla or anomalous arrangement of pancreaticobiliary ducts.

Technical information {#sec005}
---------------------

All EUS procedures were performed with a curved linear-array echoendoscope (Olympus GF-UE260, GF-UCT240; Olympus Optical Co., Tokyo, Japan) with a universal ultrasound processor (EU-ME2; Olympus Optical Co., Tokyo, Japan). All ERCP procedures were performed with a therapeutic duodenoscope (JF240, JF260V, TJF 260V; Olympus Optical Co., Tokyo, Japan). A single-lumen cannula (ERCP catheter; MTW Endoskopie, Wesel, Germany) and a guidewire (length, 450 cm; diameter, 0.06 cm; VisiGlide2; Olympus Medical Systems, Tokyo, Japan) were used for cannulation during ERCP. Three endoscopists, all of whom had experience of performing more than 300 CLAEUS procedures and more than 700 ERCP procedures, performed or supervised the CLAEUS and ERCP.

Definition {#sec006}
----------

Successful SBDC time was defined as time from viewing the orifice of the duodenal papilla to successful selective insertion of a catheter into the bile duct. Emergency ERCP procedure was defined as positive when the ERCP was performed within 24 h after arrival at the emergency room or clinic. The final diagnoses were determined by biopsy results, clinical follow-up, and surgical pathology if available. Pressure-induced bile duct collapse at D2 was considered positive when the bile duct collapsed completely and could only be identified on the basis of the biliary duct wall ([Fig 1](#pone.0235757.g001){ref-type="fig"}). "Simultaneous depiction" was considered positive when the bile and pancreatic ducts were depicted simultaneously, and the visible length of each duct was \>10 mm from the duodenal papilla ([Fig 2](#pone.0235757.g002){ref-type="fig"}). Diagnosis of PEP was made according to the Cotton's classification \[[@pone.0235757.ref012]\]. Diagnosis of acute cholangitis was made according to the Tokyo Guidelines 2018 (definite diagnosis of acute cholangitis: fever or laboratory data with evidence of inflammatory response+jaundice or abnormal liver function test+imaging study showing biliary dilation or imaging study showing stricture, stone, or stent) \[[@pone.0235757.ref013]\]. The diameter of the CBD was measured on the line drawn perpendicular to the CBD at 10--15 mm from the tip of the mucosal surface of the duodenal papilla at D2.

![^a^CLAEUS image of "bile duct collapse at D2", upper without arrow and lower with arrow.\
Pressure-induced bile duct collapse at D2 was considered positive when the bile duct collapsed completely and could only be identified on the basis of the biliary duct wall with the pressure of the tip of the CLAEUS scope (arrow). ^a^CLAEUS, curved linear array endoscopic ultrasound.](pone.0235757.g001){#pone.0235757.g001}

![^a^CLAEUS image of "simultaneous depiction of bile and pancreatic duct at D2".\
Simultaneous depiction of the bile and pancreatic ducts at D2 was considered positive when the bile duct (small arrows) and the pancreatic duct (big arrows) were depicted simultaneously on the same axis, and the visible length of both ducts is \>10 mm from the duodenal papilla. ^a^CLAEUS, curved linear array endoscopic ultrasound.](pone.0235757.g002){#pone.0235757.g002}

Thus far, as only our pilot study had asserted on the CLAEUS finding of "simultaneous depiction," validation was evaluated by assessing the inter- and intra-observer variabilities of the finding. The κ statistic is the most commonly used statistic for the evaluation of an agreement between two or more observations \[[@pone.0235757.ref014]\]. The degree of agreement was measured as a percentage of the total agreement using the κ-statistic to evaluate inter- and intra-observer variabilities. A κ value of 1 means perfect agreement, whereas a κ value of 0 means agreement equivalent to chance. The quantitative classification of the κ value is shown in [Table 1](#pone.0235757.t001){ref-type="table"}. To assess inter-observer variability, static images of CLAEUS were evaluated independently by two experienced endoscopists who were blinded to the procedural results and clinical outcomes. Furthermore, one of the two observers evaluated all images again at 6 months after the initial evaluation to assess intra-observer variability. The observer was blinded to the results of the initial evaluation. With regard to inter-observer variability, the CLAEUS finding of simultaneous depiction of bile and pancreatic ducts at D2 by observer 1 and observer 2 are shown in [Fig 3](#pone.0235757.g003){ref-type="fig"}. The κ value in the evaluation of inter-observer variability for "simultaneous depiction" was 0.65. For the intra-observer variability, the CLAEUS finding of "simultaneous depiction" by the first and second evaluations is shown in [Fig 4](#pone.0235757.g004){ref-type="fig"}. The κ value in the evaluation of intra-observer variability for "simultaneous depiction" was 0.77.

![Inter-observer variability.\
Κ value = 0.65 (95%CI: 0.47--0.83). Of the five "indecisive cases" by Endoscopist 2, Endoscopist 1 labeled one case as positive and four cases as negative.](pone.0235757.g003){#pone.0235757.g003}

![Intra-observer variability.\
Κ value = 0.77 (95%CI: 0.62--0.92).](pone.0235757.g004){#pone.0235757.g004}

10.1371/journal.pone.0235757.t001

###### Quantitative classification of kappa value.

![](pone.0235757.t001){#pone.0235757.t001g}

  kappa value   Degree of agreement
  ------------- ----------------------------
  \<.01         Less than chance agreement
  .01-.02       Slight agreement
  .21-.40       Fair agreement
  .41-.60       Moderate agreement
  .61-.80       Substantial agreement
  .81-.99       Almost perfect agreement

Statistical analysis {#sec007}
--------------------

Differences in demographic and/or clinicopathologic variables between the S group (an easy SBDC group) and R group (a difficult SBDC group) were analyzed using the chi-square and Fisher's exact tests for categorical variables and Mann-Whitney U test for continuous variables.

Based on a priori knowledge and our kappa analysis revealing validation of the CLAEUS finding of "simultaneous depiction," the following variables were incorporated into the primary multivariable model: age, sex, acute cholangitis, PAD and "simultaneous depiction."

All tests were two-tailed; *P* values \<0.05 were considered statistically significant. All statistical analyses were performed using EZR (version 1.38, <http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html>).

All authors take complete responsibility for the integrity of the data and accuracy of the data analysis.

Results and discussion {#sec008}
======================

Results {#sec009}
-------

The flow diagram of patient recruitment is shown in [Fig 5](#pone.0235757.g005){ref-type="fig"}. Among 986 ERCPs performed at our institution between July 1, 2014, and June 30, 2017, a total of 630 procedures were the cases with documented previous ERCP and 356 were naïve ERCP procedures. Of the above 356 procedures, 204 cases were excluded and 152 were the cases with CLAEUS prior to the initial ERCPs. Of excluded 204 cases, 179 were naïve ERCP cases without CLAEUS and 25 were performed CLAEUS after naïve ERCP. Detailed information of the excluded 204 cases were listed in [S1 Table](#pone.0235757.s001){ref-type="supplementary-material"}. Of 152 cases who underwent CLAEUS prior to naïve ERCP, 72 cases were excluded. Detailed diagnosis of above excluded 72 cases were listed in [S2 Table](#pone.0235757.s002){ref-type="supplementary-material"}. Finally, a total of 80 patients who underwent CLAEUS prior to initial therapeutic ERCPs were enrolled in this study. Of the above 80 cases, 16 and 64 were categorized into the R and S groups, respectively. Characteristics of the enrolled 80 cases are summarized in [Table 2](#pone.0235757.t002){ref-type="table"}. Of note, PEP was occurred 12/ 356(3.4%), 4/152(2.6%) and 2/80(2.5%) in our patient group.

![Flow diagram of patient recruitment.\
^a^CLAEUS, curved linear array endoscopic ultrasound; ^b^ERCP, endoscopic retrograde cholangiopancreatography; ^c^IQR, interquartile range. ^d^Ph, pancreatic head. ^e^PD, pancreatic duct. ^f^BD, bile duct. ^h^B-II, Billroth-II reconstruction. ^i^D2, 2^nd^ portion of duodenum.](pone.0235757.g005){#pone.0235757.g005}

10.1371/journal.pone.0235757.t002

###### Patient characteristics.

![](pone.0235757.t002){#pone.0235757.t002g}

                                                                                                        All patients (N = 80)   Group R        Group S        [^a^](#t002fn001){ref-type="table-fn"}*P* value
  ----------------------------------------------------------------------------------------------------- ----------------------- -------------- -------------- -------------------------------------------------
  N (%)                                                                                                 80 (100)                16 (20)        64 (80)        
  Age (median \[[^b^](#t002fn002){ref-type="table-fn"}IQR\])                                            71 \[62,78\]            73 \[63,83\]   70 \[61,77\]   0.47
  Male (%)                                                                                              41 (52)                 9 (56)         32 (50)        0.78
  Emergency procedure                                                                                                                                         
   Yes (%)                                                                                              17 (21)                 6 (38)         11 (17)        0.09
  Diagnosis (%)                                                                                                                                               
   Pancreatic ductal adenocarcinoma                                                                     3 (4)                   0              3 (5)          0.99
   Acute pancreatitis                                                                                   4 (5)                   1 (6)          3 (5)          0.99
   Other pancreatic disorders                                                                           3 (4)                   0              3 (5)          0.99
   Cholangiocarcinoma                                                                                   3 (4)                   2 (13)         1 (2)          0.1
   Gallbladder cancer                                                                                   2 (3)                   0              2 (3)          0.99
   Biliary stone and/or sludge                                                                          31 (39)                 1 (6)          30 (47)        0.003
   Acute cholangitis without stone, sludge, mass, or obstruction                                        17 (9)                  11 (69)        6 (9)          \<0.001
   Obstructive jaundice                                                                                 6 (8)                   1 (6)          5 (8)          0.99
   Biliary stricture                                                                                    5 (8)                   0              5 (8)          0.58
   Other biliary disorders                                                                              4 (5)                   0              4 (6)          0.58
   Abnormal [^c^](#t002fn003){ref-type="table-fn"}LFT                                                   2 (3)                   0              2 (3)          0.99
  Endoscopic findings (%)                                                                                                                                     
   Size of duodenal papilla, small                                                                      33 (41)                 7 (44)         26 (41)        0.99
   Characteristics of duodenal papilla, nodulated                                                       6 (8)                   1 (6)          5 (8)          0.99
   Peri-ampullary diverticulum, positive                                                                21 (26)                 4 (25)         17 (27)        0.99
  Endosonographic findings (%)                                                                                                                                
   Bile duct collapse                                                                                   3 (4)                   2 (13)         1 (2)          0.1
   Simultaneous [^d^](#t002fn004){ref-type="table-fn"}BD and [^e^](#t002fn005){ref-type="table-fn"}PD   19 (24)                 11 (69)        8 (13)         \<0.001
   Bile duct diameter, mm                                                                               4.1                     3.8            4.1            0.68

^a^*P* value for group R and group S.

^b^IQR, interquartile range

^c^LFT, liver function test

^d^BD, bile duct

^e^PD, pancreatic duct

Overall, the prevalence of difficult SBDC, or group R, was 20% (16/80). R group patients had less frequent diagnosis of biliary stone or sludge (R group 1 vs S group 30, *P* = 0.003) and more frequent diagnosis of acute cholangitis (R group 11 vs S group 6, *P*\<0.001). No difference in age, sex, emergency procedure rate, or diagnosis, except for the above factors, was observed between the two groups. With regard to the endoscopic findings, no difference was observed in the size of the duodenal papilla, characteristics of the duodenal papilla, or PAD. For the CLAEUS findings, "simultaneous depiction" was observed more frequently in the R group than in the S group (R group 11 vs S group 8, *P*\<0.001). CLAEUS findings of "pressure-induced bile duct collapse" and "diameter of CBD" were similar in both groups. The logistic regression analysis revealed that a CLAEUS finding of "simultaneous depiction" has a strong association with difficult SBDC (unadjusted odds ratio \[OR\]:15.4, 95% confidence interval \[CI\] 4.2--56.0; *P*\<0.001). After adjusting for confounders (age, sex, acute cholangitis, and PAD), a CLAEUS finding of "simultaneous depiction" still has an association with difficulty in SBDC ([Table 3](#pone.0235757.t003){ref-type="table"}). Furthermore, logistic regression analyses were performed by setting dependent variables not only with threshold of "insertion time above 20 minutes" but also above 5 minutes, 10 minutes and 15 minutes, and age, sex and "simultaneous depiction" as independent variables. Refractory cases (%) and odds ratio of the thresholds of 5 minutes, 10 minutes and 15 minutes were as follows; 47 (59%, OR:3.3, 95%CI: 0.96--11.2; *P* = 0.057), 23 (29%, OR:10.6, 95%CI: 3.2--35.2; *P*\<0.001), 18 (23%, OR:23.0, 95%CI: 6--88; *P*\<0.001). Except for a threshold of 5 minutes, a CLAEUS finding of "simultaneous depiction" revealed significant association with "difficult SBDC" ([S3 Table](#pone.0235757.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0235757.t003

###### Unadjusted and adjusted odds ratios for difficult [^a^](#t003fn005){ref-type="table-fn"}SBDC in patients positive for "simultaneous depiction of bile and pancreatic ducts".

![](pone.0235757.t003){#pone.0235757.t003g}

                 OR (95% CI)        *P* value
  -------------- ------------------ -----------
  Unadjusted     15.4 (4.2--56.0)   \<0.001
  Adjustment 1   14.7 (3.9--54.1)   \<0.001
  Adjustment 2   12.3 (2.5--59.6)   0.001
  Adjustment 3   12.1 (2.5--59.4)   0.002

The primary analysis (unadjusted) was performed with the logistic regression model, setting simultaneous depiction of bile and pancreatic ducts as an independent variable and difficulty in SBDC as a dependent variable.

Adjustment 1: adjusted for demographic characteristics of patients such as age and sex.

Adjustment 2: adjusted for demographic characteristics of patients as previously mentioned and presence of acute cholangitis.

Adjustment 3: adjusted for the demographic characteristics of patients as previously mentioned and presence of peri-ampullary diverticulum.

^a^SBDC, selective bile duct cannulation

Discussion {#sec010}
==========

Key findings {#sec011}
------------

This study mainly aimed to find the predictive findings on side-viewing endoscopy and/or CLAEUS for difficult SBDC on ERCP. Indeed, we demonstrated that the CLAEUS finding of "simultaneous depiction" has a strong correlation with the risk of difficult SBDC on ERCP even after adjustment for confounders.

Given the novelty of the CLAEUS finding of "simultaneous depiction," which, to our knowledge, was only reported in our pilot study \[[@pone.0235757.ref011]\], we evaluated the inter- and intra-observer variabilities to assess the feasibility and reproducibility of the CLAEUS finding. Both inter- and intra-observer variabilities in the present study indicated a substantial degree of agreement beyond chance (κ values of inter- and intra-observer variabilities were 0.65, and 0.77, respectively). Therefore, we decided to select the CLAEUS finding of "simultaneous depiction" as a candidate predictor for the risk of difficult SBDC.

The definition of difficult cannulation on ERCP varies; however, it has usually been defined according to the number of attempted cannulations and/or cannulation time, as the risk of PEP correlates with repeated and prolonged attempted cannulation \[[@pone.0235757.ref001],[@pone.0235757.ref015]--[@pone.0235757.ref017]\]. Given the above, the ideal side-viewing or CLAEUS finding to predict the risk of difficult SBDC should be obtained even without cannulating the duodenal papilla. If a certain EUS finding can play a role as a predictor for difficult SBDC, the endoscopist can prepare for a different approach such as precut or EUS-guided choledochoduodenostomy even before touching the duodenal papilla.

In performing routine CLAEUS evaluation, we perform the procedure according to the methodology given by Yamao, et al \[[@pone.0235757.ref018]\]. They advocated that with pertinent adjustment and rotation of the CLAEUS scope, left lobe of the liver, abdominal aorta with superior mesenteric artery and celiac artery, celiac lymph nodes, pancreatic body and tail, splenic artery and vein, spleen, left kidney and left adrenal gland, part of pancreatic head, portal vein with portal confluence and liver hilum, were scannable from the stomach. From the duodenal bulb, a gallbladder, portal vein, bile duct, common hepatic artery and pancreatic head were scannable. From the second portion of the duodenum (D2), superior mesenteric artery and vein, pancreatic head and ampulla, uncinated process of the pancreas and occasionally right kidney were scannable. In the above routine CLAEUS evaluation, D2 was the best station to evaluate the ampulla, bile duct and pancreatic duct precisely ([Fig 6](#pone.0235757.g006){ref-type="fig"}). Thus, we chose D2 image on CLAEUS as a candidate predictor for difficult SBDC \[[@pone.0235757.ref019]\].

![A 3-dimentional view of 2^nd^ portion of duodenum (D2) with a curved linear endoscopic ultrasound (CLAEUS).\
Route and course of pancreatic duct and common bile duct were different even though both ducts share the same opening at duodenal papilla. The CLAEUS yields views more analogous to those obtained with transabdominal ultrasound (TAUS). The view of CLAEUS is in the same plane as the scope shaft. Red fan-shape corresponds to the view of CLAEUS at D2 focusing at duodenal papilla and pancreatic duct. When focusing on main pancreatic duct on CLAEUS, pancreatic duct and bile duct colored with dark orange are visible. Only a small portion of bile duct view is available.](pone.0235757.g006){#pone.0235757.g006}

Actually, "simultaneous depiction" is a finding subtracted from retrospective investigation of the documented CLAEUS image. Even though photodocumenting a duodenal papilla is our routine requirement, close inspection of "simultaneous depiction" is not specifically required at our institution. Therefore, "simultaneous depiction" should be an image available "without specialized or particular technique", and could be a convenient measure to use as a "predictor for difficult SBDC".

Reason why the CLAEUS finding of simultaneous depiction can predict a difficult SBDC is because the finding reflects the similarity of the anatomical structure including the angle and route of both biliary and pancreatic ducts \[[@pone.0235757.ref020]\], and the above similarity would easily induce wrong cannulation of the device into the pancreatic duct instead of the biliary duct. [Fig 6](#pone.0235757.g006){ref-type="fig"} may help getting a vivid image of the 3-D structure at D2 and, moreover, understanding of bile and pancreatic ducts' anatomical similarity easily inducing unintentional cannulation of the pancreatic duct.

Of 152 cases with CLAEUS followed by naïve therapeutic ERCP, 72 cases were excluded. Given the substantial number of exclusion, there might be a concern for bias. Therefore, careful evaluation is required to see the reason for exclusion. On the other hand, as our current clinical study aims for searching "predictive finding for difficult SBDC", we needed to focus on "findings obtained without modification by certain lesion or condition". For above discussion, detailed diagnosis of the each case is required for evaluation. Regarding pancreatic disorders, pancreatic adenocarcinoma located at either pancreatic head or ampulla (4 cases), post pancreatobiliary surgery (2 cases), severe inflammation and/ or cystic lesion at pancreatic head (6 cases), severe fibrosis and/ or multiple calcification and/ or intraductal stones (4 cases) and stricture of main pancreatic duct adjacent to the ampulla (1 case) were the cases with pertinent reason for exclusion. Regarding hepatobiliary disorders, biliary tract cancer invading or including the ampulla (6 cases), benign stricture of ampulla with upstream dilatation (4 cases), impacted bile duct stone (17 cases) and bile duct inflammation (9 cases) and anomalous arrangement of bile and pancreatic ducts (1 cases) were the cases with pertinent reason for exclusion. However, in 18 cases, no images of duodenal ampulla were available (14 cases of obstructive jaundice, 2 cases of abnormal liver function test, 1 case of Lemmel's syndrome and 1 case of acute cholecystitis), suggesting that careful inspection of the pancreatic head and duodenal ampulla are required especially with above diagnosis from predicting the difficult SBDC standpoint ([S2 Table](#pone.0235757.s002){ref-type="supplementary-material"}). Especially regarding 14 cases of "obstructive jaundice", the diagnosis were made according to the finding of suspected localized caliber change of the biliary tract either on CT scan or transabdominal ultrasound with the abnormal laboratory test pattern (elevated total and direct bilirubin and gamma-GTP). Further evaluation should be planned in the future for further investigation of correlation between the finding of localized caliber change of biliary tract with "abnormal LFT pattern of obstructive jaundice" and difficulty in photodocumenting the image of duodenal papilla, including bile and pancreatic ducts.

Considering the characteristics of the R and S groups, the number of patients diagnosed with acute cholangitis and patients diagnosed with biliary stone and/or sludge were significantly higher and lower, respectively, in the R group than in the S group. With regard to acute cholangitis, it is reasonable to speculate that the inflammatory process of acute cholangitis, which was the cause of injury and edema at the duodenal papilla or bile duct, resulted in the outlet obstruction at the papilla and finally the difficult SBDC \[[@pone.0235757.ref012],[@pone.0235757.ref021],[@pone.0235757.ref022]\].

In case of biliary stone and/or sludge, the absence of biliary stone and/or sludge correlates with the smaller diameter of the biliary tract, which was one of the known risk factors for PEP \[[@pone.0235757.ref003]\].

Regarding cannulation time limits within which the regularly used cannulation technique is abandoned varies, such as 5 minutes \[[@pone.0235757.ref023]\], 10minutes \[[@pone.0235757.ref024],[@pone.0235757.ref025]\], 15 minutes \[[@pone.0235757.ref026],[@pone.0235757.ref027]\], 20 minutes \[[@pone.0235757.ref028]\] and 30minutes \[[@pone.0235757.ref029]\]. When we look at the distribution of cannulation time of our patient group, threshold of either more than 15 minutes or 20 minutes would be feasible, as with threshold of more than 5 minutes, 58% (47/80) of the patients should be included in the R group ([S1 Fig](#pone.0235757.s004){ref-type="supplementary-material"}). Furthermore, threshold of above 20 minutes was advocated and appropriately used as a threshold to perform precut by Fukatsu et al. \[[@pone.0235757.ref028]\]. Therefore, we decided to adopt cannulation time limit as more than 20 minutes.

Papilla contacts were not adopted as a condition for the definition of difficult SBDC, as it is difficult to differentiate between a simple, gentle touch at the ampulla without damage towards ampulla itself and/ or duct wall and a failed cannulation after manipulating the ampulla with excessive pressure, which causes bleeding, edema, or swelling at the mucosa and/ or duct wall, although both can be labelled as a "papilla contact."

The robustness of "simultaneous depiction" were evaluated with logistic regression analyses with cannulation time limit of being more than 5, 10 and 15 minutes as dependent variables. Only the threshold of "more than 5 minutes" didn't showed significant association (OR:3.3, 95%CI: 0.96--11.2, p = 0.057). Even though more-than-5-minute- threshold was adopted by ESGE for difficult SBDC, given the fact that 47 out of 80 cases (58%) were classified as R group in our study population and given the fact that our institution perform more than 500 cases of therapeutic ERCP and EUS annually and PEP complication rate of being 12/356(3.4%), 4/152(2.6%) and 2/80(2.5%), within appropriate range compared with data from other facility such as 3.5% \[[@pone.0235757.ref030]\], threshold of 5 minutes in our patient group is too short and divergent and its negative association with "simultaneous depiction" didn't imply the frailty of the finding.

Several studies reported on the correlation between the anatomical structure at the bile and pancreatic duct junction and surface morphology of the duodenal papilla, and one of those reports showed that the nodular type surface of the papilla accounts for 33% of the cases, showing correlation with septal type structure, for which the achievement of SBDC is the most difficult of the four papillary structure types \[[@pone.0235757.ref031],[@pone.0235757.ref032]\]. Interestingly, our study showed that the morphological and anatomical characteristics on the side-viewing scope, such as the nodular type papilla, PAD, and small-sized duodenal papilla, showed no significant difference between the R and S groups.

Strengths and limitations {#sec012}
-------------------------

The strengths of this study are as follows: the CLAEUS finding of "simultaneous depiction of both ducts" can be obtained without touching the duodenal papilla, strongly correlates with SBDC on ERCP, and possibly decreases the risk of PEP by the earlier choice of the precut approach or interventional EUS approach or by having a skilled endoscopist perform the procedure, if the finding is positive.

Despite the novel findings, this study has limitations. First, this study had a single-center, retrospective design. Therefore, the results cannot be generalized. Second, given the relatively high number of excluded cases, it is necessary to carefully apply the result to cases under different clinical setting. Considering the retrospective study design in a single center, all CLAEUS and ERCP data within a certain period were prospectively collected and evaluated, and arbitrary inclusion or exclusion of the data was minimized. Furthermore, despite the single-center design, three experienced endoscopists who often share their cases together actually performed or supervised the procedure; thus, side-viewing endoscopic findings such as "small papilla" or CLAEUS finding were obtained with certain objectivity and reproducibility, which was confirmed by our kappa analysis on "simultaneous depiction."

Considering the aforementioned novelty and limitation of our study, future perspectives related to the current study should (1) expand the study to multiple medical centers in Japan and possibly to different Asian countries, (2) increase the number of patients and carefully apply the result to cases under different clinical settings, and (3) include a heterogeneous population, considering age, sex, ethnicity, and background.

Interpretations and implications {#sec013}
--------------------------------

This study confirmed the results of our pilot study that the CLAEUS finding of simultaneous depiction of bile and pancreatic duct at D2 could significantly correlate with the risk of difficult SBDC on ERCP. If the CLAEUS finding of "simultaneous depiction" were used as the tool to estimate the risk of difficult SBDC in advance, a quick CLAEUS prior to ERCP could predict and allow the endoscopist to prepare for difficult ERCP cases without physically cannulating a papilla, with promising feasibility and reproducibility. By predicting the difficulty in SBDC, an endoscopist can establish pertinent planning when performing ERCP, such as setting shorter time limits and selecting alternative devices, techniques, and skilled endoscopist, to perform SBDC with minimal invasiveness. Using the CLAEUS finding of "simultaneous depiction," the endoscopist may efficiently minimize complications including PEP or unnecessary disruption of the duodenal papilla by precut in difficult SBDC cases.

Controversies {#sec014}
-------------

This study suggested that the three-dimensional structure and anatomy of the bile and pancreatic ducts at the duodenal papilla is a critical factor for predicting difficult SBDC. Our results may provoke further controversy regarding the re-evaluation of "truly important findings for predicting difficult SBDC," especially the presence of a peri-ampullary diverticulum or the size of the duodenal papilla, by comparing these findings with the "simultaneous depiction of both ducts."

Future research directions {#sec015}
--------------------------

A future prospective study is necessary to establish the treatment algorithm in cases with CLAEUS finding of simultaneous depiction of bile and pancreatic ducts. In future prospective studies, it may be feasible to evaluate whether adding other endoscopic or endosonographic findings and/ or characteristics (number of precisely and objectively defined "attempted cannulations" with cannulation time, for example) for cases with "simultaneous depiction" can contribute to not only more successful SBDC but also fewer ERCP complications including PEP.

Supporting information {#sec016}
======================

###### Detailed diagnosis of excluded 204 cases.

(DOCX)

###### 

Click here for additional data file.

###### Characteristics of patients undergoing ^a^CLAEUS-naïve ^b^ERCP.

(DOCX)

###### 

Click here for additional data file.

###### Unadjusted and adjusted odds ratios for difficult ^a^SBDC in patients positive for "simultaneous depiction of bile and pancreatic ducts".

(DOCX)

###### 

Click here for additional data file.

###### Distribution of "cannulation time of the patients underwent naïve ERCP after CLAEUS".

(TIF)

###### 

Click here for additional data file.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The discussed study is a single center, retrospective cohort study, including 80 patients. All patients have curved linear array endoscopic ultrasound (CLAEUS) before endoscopic retrograde cholangiopancreatography (ERCP).

The general aim of the study, was to define predictors of difficult selective bile duct cannulation (SBDC).

Hereby difficult is described as the simultaneous depiction of bile and pancreatic ducts at the second portion of the duodenum farther than 10 mm away from the papilla.

It therefore has been concluded, that if a CLAEUS is done in advance, the risk of a post-ERCP pancreatitis, as well as the risk of complications is reduced.

Limitations of the study:

I find it irritating, that the division of the patients into two groups were on the basis of the duration of the examination, and more importantly, that the used threshold, was define by the study group. Is this threshold robust? It seems to be necessary, that this threshold is varied. Furthermore additional factors in the definition of the threshold should be considered, such as the mentioned number of papilla contacts.

In Addition the number of patients were initially 356, but included in the study were only 80. This strong selected patient group I find very odd and would like a more detailed explanation of why 356 patients were included in the first place.

Reviewer \#2: The work „Endosonographic finding of the simultaneous depiction of bile and pancreatic ducts can predict difficult biliary cannulation on endoscopic retrograde cholangiopancreaticography" by Susumu Shinoura et. Al addresses an important question in the field of interventional endocopy: How is it possible to predict a difficult difficult approach to the biliary system before conventional ERCP. In the past, several attempts have been made to improve pre-therapeutic certainity about subsequent risks for patients undergoing ERCP and therefore making an early decision for possible alternative strategies like precut papillotomy or transduodenal approaches for bile drainage.

The manuscript is technically sound, the statistical analysis appears to be correct, especially the different statistical tests are chosen correctly for the distinct analyses. Both strength and limitations of the study are well described and discussed together with the current literature.

In General, I see only some minor points to be addressed:

1\. As the authors state correctly the present work is based on a retrospective analysis of EUS images. This is basically discussed as a potential bias of the study. But I would recommend to further comment on an essential cause of additional errors: It is not clear whether the examiners intended to document a simultaneous depiction. There might have been a number of undocumented patients with "simultaneous depiction" but simply were not documented by the examiners. Is there standard protocol of photo-documentation in EUS, especially in D2 Position to make sure there is a high possibility that a "double depiction" is always being documented? Please comment on that more precisely.

2\. In the present version of the manuscript I see some frailty with aspect to image- and graphic presentation. It might be helpful for a less specialized readership to provide a graphical overview that contains: (i) Overview of main anatomical structures, (ii) position of the echoendoscope in the duodenum and (iii) a display of "simultaneous depiction".

I would recommend to better center the region of interest within the images of (i) bile duct collapse (Fig. 1) and simultaneous depiction (Figure 2).

3\. Most parts of the text are well written in an intelligible fashion, but it might profit at a very few parts from a stylistic correction by a native speaker: E.g.: "As post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis as a complication49 of ERCP becomes (may become) fatal..."

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Martin Müller, MD, Dept. of Gastroenterology, Ulm University, Germany

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Editor:

Thank you for inviting us to submit a revised draft of our manuscript entitled "Endosonographic finding of the simultaneous depiction of bile and pancreatic ducts can predict difficult biliary cannulation on endoscopic retrograde cholangiopancreatography" to PLOS ONE. We also appreciate the time and effort you and each of the reviewers have dedicated to providing insightful feedback on ways to strengthen our paper. Thus, it is with great pleasure that we resubmit our article for further consideration. We have incorporated changes that reflect the detailed suggestions you have graciously provided. We also hope that our edits and the responses we provide below satisfactorily address all the issues and concerns you and the reviewers have noted.

To facilitate your review of our revisions, the following is a point-by-point response to the questions and comments delivered in your letter dated April 22, 2020.

Thank you very much for reviewing our manuscript and offering valuable advice.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

RESPONSE

We confirmed that our manuscript met the PLOS ONE's style requirements according to your advice.

2\. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. \[\"Part of the submitted data was used for our Pilot study, which was attached as \"other\" with subtitle \"SHINOURA Article of pilot study\".\] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

RESPONSE

The following explanation has been provided in the cover letter regarding our previous pilot study: "The pilot study (Shinoura S, Kenji C. Use of curved-linear array endoscopic ultrasonography findings to predict difficulty in biliary access during endoscopic retrograde cholangiopancreatography. EC Gastroenterology and Digestive System. 2018; 5: 306-314) was performed with a different time period from the current manuscript. Furthermore, the pilot study compared subtracted cases instead of comparing all the consecutive cases within the time period, which was different from the current manuscript. The study design of the pilot study can be described as a case control study instead of retrospective cohort study, which was also substantially different from this manuscript. The pilot study was previously peer-reviewed and published. Therefore, though the pilot study provided an inspiration, the current study does not constitute a dual publication and thus, the pilot study could be included in the current manuscript as a reference."

3\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

RESPONSE

We have put the reason for data access restriction in the cover letter (starting at LINE 46) and researchers who meet the criteria for access to confidential data can access using the following contact details as written in the cover letter. "Data are available from the Institutional Data Access / Ethics Committee (contact via SS or <xx031112@pref.okinawa.lg.jp>) for researchers who meet the criteria for access to confidential data."

4\. comments from editors and reviewers

\(1\) Especially the robustness of the chosen threshold should be addressed and possibly substantiated by a cross-validation analysis.

RESPONSE

The definition of difficult cannulation on ERCP varies, thus, it is understandable that choosing only one threshold of "more than 20 minutes for SBDC" would be criticized as an arbitral choice. To ascertain the robustness of the finding of "simultaneous depiction", we analyzed additional thresholds of 5, 10 and 15 minutes as not only the threshold of more than 20 minutes, but also those thresholds were advocated in previous studies (This in the Result section starting from LINE 232). Except for a threshold of more than 5 minutes, "simultaneous depiction" could significantly identify "difficult SBDC" cases (supplementary table 3). Furthermore, regarding threshold of 5 minutes, when evaluating cannulation time distribution of 80 patients (supplementary figure 1), 47 out of 80 cases (58%) were included in the "refractory group" with the threshold of more than 5 minutes. Actually, our institution perform more than 500 cases of therapeutic ERCP and EUS annually and complication rate such as post ERCP pancreatitis was 12/356 (3.4%), 4/152 (2.6%) and 2/80 (2.5%), respectively, and the complication rate was not different from those reported from other facilities, such as 3.5%. Therefore, the threshold of more than 5 minutes of cannulation time did not reflect the "true difficulty" in cannulation at our institute. Therefore, no apparent frailty was seen when more than 5-minute cannulation time was not significant (The above have been included in the Discussion section, starting at LINE 348). Unfortunately, we could not perform a cross-validation analysis due to shortage of manpower under the corona virus pandemic and restriction in accessing the data due to off-limit policy of the institution. However, the above additional analyses of the data could support the robustness of the "simultaneous depiction" to predict difficult SBDC.

\(2\) I find it irritating, that the division of the patients into two groups were on the basis of the duration of the examination, and more importantly, that the used threshold, was define by the study group. Is this threshold robust? It seems to be necessary, that this threshold is varied. Furthermore additional factors in the definition of the threshold should be considered, such as the mentioned number of papilla contacts.

RESPONSE

With regard to the robustness of the finding, we considered additional evaluation and discussion in 4-(1) provide answer to your area of concern. Furthermore, the following discussion has been added in the manuscript (in the DISCUSSION section starting from LINE 356): "Papilla contacts were not adopted as a condition for the definition of difficult SBDC, as it is difficult to differentiate the simple, gentle touch at the ampulla. In addition, failed cannulation after manipulating the ampulla with excessive pressure causes bleeding, edema, or swelling at the mucosa and or duct wall.\"

\(3\) In Addition the number of patients were initially 356, but included in the study were only 80. This strong selected patient group I find very odd and would like a more detailed explanation of why 356 patients were included in the first place.

RESPONSE

Of the 356 naïve ERCP cases, the cases with and without CLAEUS being performed after naïve ERCP were 25 and 179, respectively. We have indicated this in the flowchart (Figure 5) and table (supplementary table 1) in the result (This is indicated in the RESULT section starting from LINE 194) and further commented on in the discussion section (starting from LINE 313). Regarding 152 cases with CLAEUS followed by naïve therapeutic ERCP, 72 cases were excluded. Additional list was also added to describe the diagnosis and detailed information of each excluded case (supplementary table 2). There were 18 cases without available image of the duodenal papilla and or D2 image. This was commented on in the Result section (starting from LINE 331): "Especially with regard to the 14 cases of "obstructive jaundice", the diagnoses were made according to the finding of suspected localized caliber change of the biliary tract either on CT scan or trans abdominal ultrasound with the abnormal laboratory test pattern (elevated total and direct bilirubin and gamma-GTP). Further evaluation should be planned in the future for further investigation of the correlation between the finding of localized caliber change of biliary tract with "abnormal LFT pattern of obstructive jaundice" and difficulty in photo-documenting the image of duodenal papilla, including bile and pancreatic ducts."

\(4\) As the authors state correctly the present work is based on a retrospective analysis of EUS images. This is basically discussed as a potential bias of the study. But I would recommend to further comment on an essential cause of additional errors: It is not clear whether the examiners intended to document a simultaneous depiction. There might have been a number of undocumented patients with "simultaneous depiction" but simply were not documented by the examiners. Is there standard protocol of photo-documentation in EUS, especially in D2 Position to make sure there is a high possibility that a "double depiction" is always being documented? Please comment on that more precisely.

RESPONSE

We did not intentionally evaluate the "simultaneous depiction" at D2. However, it is our routine to visualize and photo-document the duodenal papilla and both ducts from the papilla. We consider the above comment further reinforce the usefulness of our finding as a tool for prediction of difficult SBDC. We have reflected this in the Discussion section, starting from LINE 292.

Our response here is similar to that provided for reviewer comment 4-(3): "14 out of 18 cases with unavailable photo-documentation of D2 were the cases with obstructive jaundice. The cases were diagnosed with abnormality of the biliary tract caliber and abnormal liver function test (supplementary table 2). We could not clarify the reason why D2 was difficult to visualize in those cases, and we commented that future studies will be required.

We did not generalize our routine step by step methodology of the routine CLAEUS. We described it in detail in the Discussion section (starting from LINE 280). In addition to above, we specifically added the illustration (figure 6) to help the understanding of the readers that D2 inspection is important in the evaluation of the duodenal papilla, bile duct, and pancreatic duct structure. We added further explanation on the correlation of "simultaneous depiction" and difficult SBDC in the Discussion section (starting from LINE 310).

(5)In the present version of the manuscript I see some frailty with aspect to image- and graphic presentation. It might be helpful for a less specialized readership to provide a graphical overview that contains: (i) Overview of main anatomical structures, (ii) position of the echoendoscope in the duodenum and (iii) a display of "simultaneous depiction".

I would recommend to better center the region of interest within the images of (i) bile duct collapse (Fig. 1) and simultaneous depiction (Figure 2).

RESPONSE

For a less specialized readership, we have added an illustration of the D2 (figure 6) to help the understanding of the graphical overview, with the main anatomical structures, position of the CLAEUS scope at D2, and the view which could be gained from the position. This comment has been added in the Discussion section (starting from LINE 280).

Regarding Figures 1 and 2, we did our best to center the region of interest of the (i) bile duct collapse (Fig. 1) and the simultaneous depiction.

\(6\) it might profit at a very few parts from a stylistic correction by a native speaker: E.g.: "As post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis as a complication49 of ERCP becomes (may become) fatal..."

RESPONSE

As the reviewer suggested, this part has been revised by a native English speaker. The sentence in the Introduction section, starting from LINE 47 now reads as follows: "Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) as a complication of ERCP may become fatal......"

Again, thank you for giving us the opportunity to strengthen our manuscript with your valuable comments and queries. We have significantly improved our manuscript by incorporating your feedback and we hope that these revisions makes our submission acceptable and suitable for publication in your esteemed journal.

Sincerely,

Shinichiro Ueda, MD., PhD.

Department of Clinical Research and Quality Management

University of the Ryukyus Graduate School of Medicine

207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan

Tel: +81-98-895-1195

Fax: +81-98-895-1447

E-mail: <blessyou@med.u-ryukyu.ac.jp>
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Dear Dr. Ueda,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Hans A Kestler

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The comments were addressed and precisely differentiated in the revised version. They have added helpful explanations for the reader.

Reviewer \#2: The authors have fully adressed all of my comments.

(Only due to formatting reasons) the Resolution of the Pictures is quite low, this should be corrected within the final version of the manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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Dear Dr. Ueda:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Hans A Kestler

Academic Editor

PLOS ONE
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